News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
New York
Friedreich’s ataxia
Lexeo’s Gene Therapy Shows Early Promise for Friedreich’s Ataxia Cardiomyopathy
Lexeo Therapeutics’ investigational gene therapy reduces left ventricular volume and wall thickness in patients with Friedreich’s ataxia, according to a small study.
July 15, 2024
·
2 min read
·
Tristan Manalac
PRESS RELEASES
Press Releases
OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma
April 30, 2026
·
11 min read
Press Releases
Precision Neuroscience™ Partners With UChicago Medicine Researchers to Advance Brain–Computer Interface Research
April 30, 2026
·
2 min read
Press Releases
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
April 30, 2026
·
1 min read
Press Releases
Fesarius Therapeutics demonstrates the science that establishes DermiSphere™ hDRT in a class of its own
April 30, 2026
·
3 min read
Press Releases
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
April 30, 2026
·
1 min read
Press Releases
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
April 30, 2026
·
5 min read
Press Releases
SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results
April 30, 2026
·
1 min read
Press Releases
Immunic to Participate in Investor and Medical Conferences in May 2026
April 30, 2026
·
5 min read
Press Releases
Photon Raises $16M Series A to Give Patients Control Over Their Prescriptions and Bring Transparency to Pharmacy
April 30, 2026
·
6 min read
Press Releases
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
April 29, 2026
·
8 min read
Press Releases
Vaccinex Reports 2025 Annual Financial Results
April 29, 2026
·
1 min read
Press Releases
AI Detection and Repurposed Drugs Signal New Era in Food Allergy Research at Food Allergy Fund Summit
April 29, 2026
·
5 min read
Press Releases
Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma
April 29, 2026
·
15 min read
Press Releases
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May 2026
April 29, 2026
·
3 min read
Press Releases
Regeneron Reports First Quarter 2026 Financial and Operating Results
April 29, 2026
·
30 min read
Press Releases
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
April 29, 2026
·
9 min read
Press Releases
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder
April 28, 2026
·
2 min read
Press Releases
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
April 28, 2026
·
7 min read
Press Releases
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
April 28, 2026
·
10 min read
Press Releases
AviadoBio Announces Agreement with Apertura Gene Therapy to License TfR1 CapX™, a Next-Generation Blood-Brain Barrier-Crossing Capsid
April 28, 2026
·
6 min read
